SUMMARY The cardiovascular effects of the cardioselective beta agonist prenalterol have been studied in nine patients with severe chronic congestive cardiac failure and in six patients with left ventricular dysfunction resulting from previous myocardial infarction. In the patients with cardiac failure intravenous prenalterol in a dosage of 1.5 ,ug/kg bodyweight increased the cardiac index from 1.8+0*1 to 2*1±0*1 /min per m2 and the left ventricular ejection fraction from 22+3 to 28+3%. There was a modest but significant increase in heart rate from 76+3 to 87+4 beats/min. Systemic vascular resistance fell from 2285±51 to 2041 + 534 dynes s-I cm-5. On exercise, the left ventricular filling pressure fell from 33+6 to 26±3 and both cardiac index and stroke index increased by 13% and 16%, respectively. There was no significant change in heart rate or systemic blood pressure. In the patients with left ventricular dysfunction, coronary sinus blood flow increased from 107+ 11 to 133+12 ml/min but the increase in myocardial oxygen consumption was small and not significant (11.6± 1l2 and 14*5± 1-9 m/min). In all patients there was no evidence that prenalterol was arrhythmogenic.
There has been a resurgence of interest in the management of the patient with congestive cardiac failure. Vasodilator therapy has been shown to be effective in increasing cardiac output and reducing left ventricular filling pressure in patients with both acute and chronic cardiac failure I -5. Inotropic drugs can also be of value in improving cardiac performance but sideeffects can be troublesome. Isoprenaline is a potent beta-adrenoreceptor agonist but provokes tachycardia, can precipitate arrhythmias, and increases myocardial oxygen consumption.6 Dobutamine has been shown to have significant inotropic properties7 8 but in patients after open-heart surgery a chronotropic effect similar to that of isoprenaline was found.9 The endogenous catecholamine dopamine has been shown to be a useful inotropic agent and in addition dilates renal control and splanchic vessels. As with isoprenaline, however, it may provoke ventricular arrhythmias, and in addition it has alpha-adrenergic effects.'0 A combination of vasodilator therapy and inotropic agents has also been shown to be of value. " l 12 Prenalterol (S-(-)-1-(4hydroxyphenoxy)-3 isoAccepted for publication 3 November 1981 propylamino propanol-2 hydrochloride) is a new selective betal-adrenoreceptor agonist which has been described as having potent inotropic effects with little chronotropic action. 13 Johnsson et al. 4 have reported that, in human volunteers, prenalterol when administered either orally or intravenously produced an increase in myocardial contractility with little or no increase in heart rate. Ariniegoet al.'lhave confirmed these findings in patients with acute myocardial infarction and in addition suggested that prenalterol was a useful antidote to the unwanted cardiac effects of beta-adrenoreceptor blocking drugs. Hutton et al. 16 studied the haemodynamic effects in patients with coronary heart disease using both invasive and non-invasive methods and concluded that prenalterol enhanced the contractile state of the myocardium without altering heart rate. Reiz Six male patients with a mean age of 47+4 (37 to 59 years), who had sustained a previous myocardial infarction and had angiographic evidence of regional wall abnormality, were studied at the time of cardiac catheterisation. All drug treatment was discontinued over the 48 hours before the study.
Systemic blood pressure was obtained from an intra-arterial catheter placed in the ascending aorta via the femoral artery. Pulmonary pressure, pulmonary capillary wedge pressure, and cardiac output were measured as described above. A 7F double thermistor catheter (Wilton-Webster) was introduced into a left median antecubital vein and advanced into the proximal 1 to 2 cm of the coronary sinus. The catheter tip was not moved during the course of the study. Coronary sinus blood flow was measured using a continuous infusion thermodilution technique via a constant infusion of a 0 90/o saline solution at 60 ml/min for 30 seconds.'8 The reproducibility of coronary sinus blood flow measurements using this technique is 3±2% and in this study relative effects were assessed with each patient acting as his own control. Simultaneous blood samples were obtained from the aorta and the coronary sinus and were assayed for oxygen content using an Instrumentation Laboratories CoOximeter 282.
Prenalterol was infused intravenously in a dosage of 1.5 mg in 50 ml of dextrose over a 30 minute period using a calibrated infusion pump.
Statistical analysis in both studies was performed using Student's paired t test, a p value of <0-05 being considered significant. The results are expressed as the mean + standard error of the mean. Results
CALCULATED VARIABLES
Systemic vascular resistance (SVR)= (MBP-RA) x 80 dynes s ' cm5 CO (p<002) and in left ventricular ejection fraction from 22+3 to 28+3% (p<0.02) (Fig. 1 ). There was a modest but significant increase in heart rate from 76+3 to 87±4 beats/min (p<0005) and in systolic blood pressure from 120±6 to 130± 7 mmHg (p<0 02) (Fig. 2 (Fig. 3) . All Table 2 . In these patients with left ventricular regional wall abnormalities, prenalterol increased cardiac index from 3*1±+0*2 to 3 *6+0-3 /min per m2 (p<0 .02). There was a modest but significant increase in heart rate from 74±4 to 90±6 beats/min (p<0*005). There were no significant changes in systemic blood pressure or in left ventricular filling pres- sure. Coronary sinus blood flow increased from 107+11 to 133+12 ml/min (p<0-05) but with an associated but not significant increase in myocardial oxygen consumption from 116l1*2 to 14-5t19 ml/min (Fig. 4) .
Discussion
This study has shown that prenalterol enhances the cardiac performance of patients with congestive cardiac failure both at rest and during dynamic exercise Prenalterol has been shown to be effective orally in both normal volunteers and patients with congestive cardiac failure where an increase in cardiac output and reduction in left ventricular filling pressure were found with an improvement in functional exercise capacity.27 It therefore seems appropriate to evaluate the haemodynamic effects of oral prenalterol in chronic congestive cardiac failure over a prolonged period, though Braunwald has raised the possibility that prolonged administration of a beta-adrenergic agonist might lead to alteration of haemodynamic responses, a consequence of "down-regulation" of the beta receptor. 28 This study has shown that intravenous prenalterol improves cardiac performance in patients with chronic congestive cardiac failure, and a placebocontrolled trial of oral prenalterol in such patients appears indicated.
